Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 105

Results For "VAI"

1986 News Found

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
News | March 03, 2023

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event


5 crore health records of individuals linked to their ABHA for anytime access
Policy | March 01, 2023

5 crore health records of individuals linked to their ABHA for anytime access

With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)


Department of Pharmaceuticals to celebrate 5th Jan Aushadhi Diwas on March 7
News | March 01, 2023

Department of Pharmaceuticals to celebrate 5th Jan Aushadhi Diwas on March 7

Jan Aushadhi Diwas celebrations to generate awareness about the usages of generic medicines and benefits of Jan Aushadhi Pariyojana


Ayush Minister inaugurates first Chintan Shivir
News | March 01, 2023

Ayush Minister inaugurates first Chintan Shivir

Sonowal exhorted young researchers and scientist to work on evidence based scientific research


AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India
News | March 01, 2023

AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India

Receives regulatory approval for its molecule ‘Selumetinib’ in India


NATCO launches generic Pomalidomide Capsules in Canada
News | March 01, 2023

NATCO launches generic Pomalidomide Capsules in Canada

Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules


EMA recommends refusal of the marketing authorization for Lagevrio
News | February 25, 2023

EMA recommends refusal of the marketing authorization for Lagevrio

Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.


Pfizer and BioNTech submit sBLA for approval of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine
Drug Approval | February 25, 2023

Pfizer and BioNTech submit sBLA for approval of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine

This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.